Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Targeted cancer therapies often face challenges due to the complex, interwoven nature of signaling pathways.
• The RAS signaling network in cancer is particularly complex and difficult to target effectively.
• Current methods for evaluating drug response at the genomic level need improvement for personalized medicine.

Purpose of the Study:

• To develop and validate a gene-expression-based biomarker for assessing RAS network activity in non-small cell lung cancer (NSCLC).
• To identify drugs that are effective in treating NSCLC based on global RAS network activity.
• To provide a genomic strategy for classifying and targeting complex signaling networks in cancer treatment.

Main Methods:

• Utilized a gene-expression biomarker to measure RAS network activity in NSCLC cell lines.
• Screened a panel of over 360 compounds and fractions for efficacy correlated with RAS network activity.
• Conducted mechanistic studies to elucidate the effects of targeted inhibition on cancer cell signaling pathways.

Main Results:

• Identified co-inhibition of Epidermal Growth Factor Receptor (EGFR) and MEK as the most effective treatment for RAS-active NSCLC.
• RAS activity was detected in both RAS-mutant and wild-type NSCLC lines, indicating a broad applicability of the biomarker.
• EGFR and MEK co-inhibition induced apoptosis and simultaneously blocked key downstream signaling nodes (EGFR-RAS-RAF-MEK-ERK and EGFR-PI3K-AKT-RPS6) in RAS-active NSCLC.

Conclusions:

• A comprehensive genomic strategy can personalize NSCLC treatment by targeting RAS network dysregulation.
• Combined EGFR and MEK inhibition offers a promising therapeutic approach for RAS-active NSCLC.
• This study provides proof-of-concept for a genomic approach to classify and target complex signaling networks in cancer.